CompletedNot Applicable

ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS

Pakistan80 participantsStarted 2023-05-14

Plain-language summary

This randomized controlled trial was conducted at the Department of Medicine and Diabetes of Mayo Hospital/King Edward Medical University, Lahore, over one year. A total of 80 patients with type 2 diabetes and normal serum uric acid were randomly assigned to two groups: Group A received allopurinol with lisinopril, and Group B received lisinopril alone. Patients were monitored every three months for serum creatinine, spot urine albumin, and serum uric acid levels. The primary endpoint was a \>300 mg/L increase in urine albumin from baseline. Blood pressure was managed with agents other than ACE inhibitors if required.

Who can participate

Age range35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with type 2 diabetes mellitus on oral hypoglycemic agents, serum creatinine levels less than 1.1 mg/dL, and serum uric acid levels between 5.5-6.5 mg/dL for males and 5-6 mg/dL for females Exclusion Criteria: * patients with tumor lysis syndrome, chronic kidney disease from other causes (e.g., hypertension, glomerulonephritis, polycystic kidney disease, or hydronephrosis), those on medications that could cause hyperuricemia (such as thiazide diuretics) or those on drugs that may induce proteinuria (e.g., NSAIDs, cyclosporine, penicillamine, or gold). Patients with uric acid levels exceeding 7 mg/dL were also excluded

What they're measuring

Urinary Albumin

Timeframe: 3 months

Trial details

NCT IDNCT07177898

SponsorNarowal Medical College

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-09-23

View on ClinicalTrials.gov More Diabetic Kidney Disease (DKD) trials